Valerenic acid and Valeriana officinalis extracts delay onset of Pentylenetetrazole (PTZ)-Induced seizures in adult Danio rerio (Zebrafish)

BMC Complementary and Alternative Medicine

José G. Ortíz¹  Lisa M. Del Valle-Mojica¹  Bianca A. Torres-Hernández¹ 

[1] Neuropharmacology Laboratory, Pharmacology and Toxicology, Department University of Puerto Rico- Medical Science Campus, San Juan 00936-5067, Puerto Rico

关键词: Pentylenetetrazole-induced seizures;    Clonic-like seizures;    Clonazepam;    Phenytoin;    Antiepileptic drugs (AEDs);    Herbal-Drug Interaction;   

Others  :  1220035
DOI  :  10.1186/s12906-015-0731-3

 received in 2014-10-07, accepted in 2015-06-18,  发布年份 2015

【 摘 要 】

Background

Anticonvulsant properties have been attributed to extracts of the herbal medicine Valeriana officinalis. Our aims were to examine the anticonvulsant properties of valerenic acid and valerian extracts and to determine whether valerian preparations interact with the activity of other anti-epileptic drugs (phenytoin or clonazepam). To achieve these goals, we validated the adult zebrafish, Danio rerio, as an animal model for studying anticonvulsant drugs.

Methods

All drug treatments were administered by immersion in water containing the drug. For assays of anticonvulsant activity, zebrafish were pretreated with: anti-epileptic drugs, valerenic acid, aqueous or ethanolic valerian extracts, or mixtures (phenytoin or clonazepam with valerenic acid or valerian extracts). Seizures were then induced with pentylenetetrazole (PTZ). A behavioral scale was developed for scoring PTZ-induced seizures in adult zebrafish. The seizure latency was evaluated for all pretreatments and control, untreated fish. Valerenic acid and both aqueous and ethanolic extracts of valerian root were also evaluated for their ability to improve survival after pentylenetetrazole-challenge. The assay was validated by comparison with well-studied anticonvulsant drugs (phenytoin, clonazepam, gabapentin and valproate). One-way ANOVA followed by Tukey post-hoc test was performed, using a p < 0.05 level of significance. All treatments were compared with the untreated animals and with the other pretreatments.

Results

After exposure to pentylenetetrazole, zebrafish exhibited a series of stereotypical behaviors prior to the appearance of clonic-like movements—convulsions. Both valerenic acid and valerian extracts (aqueous and ethanolic) significantly extended the latency period to the onset of seizure (convulsion) in adult zebrafish. The ethanolic valerian extract was a more potent anticonvulsant than the aqueous extract. Valerenic acid and both valerian extracts interacted synergistically with clonazepam to extended the latency period to the onset of seizure. Phenytoin showed interaction only with the ethanolic valerian extracts.

Conclusions

Valerenic acid and valerian extracts have anticonvulsant properties in adult zebrafish. Valerian extracts markedly enhanced the anticonvulsant effect of both clonazepam and phenytoin, and could contribute to therapy of epileptic patients.

【 授权许可】

   
2015 Torres-Hernández et al.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

Fig. 4.

Fig. 5.

【 参考文献 】

• [1]Berg AT, Berkovic SF, Brodie MJ, Buchhalter J, Cross JH, van Emde Boas W, Engel J, French J, Glauser T, Mathern GW, Moshé SL, Nordli D, Plouin P, Scheffer IE. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005–2009. Epilepsia. 2010; 51:676-85.
• [2]Epilepsy. [http://www.who.int/mediacentre/factsheets/fs999/en/##]
• [3]Schmidt D. Drug treatment of epilepsy: options and limitations. Epilepsy Behav. 2009; 15:56-65.
• [4]Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000; 342:314-9.
• [5]Cramer JA, Glassman M, Rienzi V. The relationship between poor medication compliance and seizures. Epilepsy Behav. 2002; 3:338-42.
• [6]Chen H-F, Tsai Y-F, Lin Y-P, Shih M-S, Chen J-C. The relationships among medicine symptom distress, self-efficacy, patient-provider relationship, and medication compliance in patients with epilepsy. Epilepsy Behav. 2010; 19:43-9.
• [7]Enríquez-Cáceres M, Soto-Santillana M. Non-compliance with pharmacological treatment in patients with epilepsy. Rev Neurol. 2006; 42:647-54.
• [8]Hessen E, Lossius MI, Reinvang I, Gjerstad L. Influence of major antiepileptic drugs on attention, reaction time, and speed of information processing: results from a randomized, double-blind, placebo-controlled withdrawal study of seizure-free epilepsy patients receiving monotherapy. Epilepsia. 2006; 47:2038-45.
• [9]Luna-Tortós C, Fedrowitz M, Löscher W. Evaluation of transport of common antiepileptic drugs by human multidrug resistance-associated proteins (MRP1, 2 and 5) that are overexpressed in pharmacoresistant epilepsy. Neuropharmacology. 2010; 58:1019-32.
• [10]Lazarowski A, Lubieniecki F, Camarero S, Pomata H, Bartuluchi M, Sevlever G, Taratuto AL. Multidrug resistance proteins in tuberous sclerosis and refractory epilepsy. Pediatr Neurol. 2004; 30:102-6.
• [11]McConnell BV, Applegate M, Keniston A, Kluger B, Maa EH. Use of complementary and alternative medicine in an urban county hospital epilepsy clinic. Epilepsy Behav. 2014; 34:73-6.
• [12]Metcalfe A, Williams J, McChesney J, Patten SB, Jetté N. Use of complementary and alternative medicine by those with a chronic disease and the general population--results of a national population based survey. BMC Complement Altern Med. 2010; 10:58. BioMed Central Full Text
• [13]Barnes PM, Bloom B, Nahin RL. Complementary and alternative medicine use among adults and children: United States. Natl Health Stat Report. 2007; 2008:1-23.
• [14]Fasinu PS, Bouic PJ, Rosenkranz B. An overview of the evidence and mechanisms of herb-drug interactions. Front Pharmacol. 2012; 3:69.
• [15]Lucas RA, Gilfillan DJ, Bergstrom RF. A pharmacokinetic interaction between carbamazepine and olanzapine: observations on possible mechanism. Eur J Clin Pharmacol. 1998; 54:639-43.
• [16]Landmark Johannessen C, Patsalos PN. Interactions between antiepileptic drugs and herbal medicines. Boletín Latinoam y del Caribe Plantas Med y Aromáticas. 2008; 7:108-18.
• [17]Kupiec T, Raj V. Fatal seizures due to potential herb-drug interactions with Ginkgo biloba. J Anal Toxicol. 2005; 29:755-8.
• [18]Monograph. Valeriana officinalis. Altern Med Rev. 2004; 9:438-41.
• [19]Eadie MJ. Could valerian have been the first anticonvulsant? Epilepsia. 2004; 45:1338-43.
• [20]Tagarelli G, Tagarelli A, Liguori M, Piro A. Treating epilepsy in Italy between XIX and XX century. J Ethnopharmacol. 2013; 145:608-13.
• [21]Spinella M. Herbal medicines and epilepsy: the potential for benefit and adverse effects. Epilepsy Behav. 2001; 2:524-32.
• [22]Miller LG. Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions. Arch Intern Med. 1998; 158:2200-11.
• [23]Khayat Nouri MH, Abbas Abad AN. Gabaergic system role in aqueous extract of Valeriana officinalis L. root on PTZ-induced clonic seizure threshold in mice. African J Pharm Pharmacol. 2011; 5:1212-7.
• [24]Rezvani ME, Roohbakhsh A, Allahtavakoli M, Shamsizadeh A. Anticonvulsant effect of aqueous extract of Valeriana officinalis in amygdala-kindled rats: possible involvement of adenosine. J Ethnopharmacol. 2010; 127:313-8.
• [25]Hiller K-O, Zetler G. Neuropharmacological studies on ethanol extracts of valeriana officinalisL.: behavioural and anticonvulsant properties. Phyther Res. 1996; 10:145-51.
• [26]Upton R, Petrone C (Eds): Valerian Root Valeriana Officinalis Analytical, Quality Control, and Therapeutic Monograph. Santa Cruz, CA: American Herbal Pharmacopoeia (AHP); 1999.
• [27]Patočka J, Jakl J. Biomedically relevant chemical constituents of Valeriana officinalis. J Appl Biomed. 2010; 8:11-8.
• [28]Gao XQ, Björk L. Valerenic acid derivatives and valepotriates among individuals, varieties and species of Valeriana. Fitoterapia. 2000; 71:19-24.
• [29]Khom S, Baburin I, Timin E, Hohaus A, Trauner G, Kopp B, Hering S. Valerenic acid potentiates and inhibits GABA(A) receptors: molecular mechanism and subunit specificity. Neuropharmacology. 2007; 53:178-87.
• [30]Benke D, Barberis A, Kopp S, Altmann K-H, Schubiger M, Vogt KE, Rudolph U, Möhler H. GABA A receptors as in vivo substrate for the anxiolytic action of valerenic acid, a major constituent of valerian root extracts. Neuropharmacology. 2009; 56:174-81.
• [31]Del Valle-Mojica LM, Ortíz JG. Anxiolytic properties of valeriana officinalis in the zebrafish: a possible role for metabotropic glutamate receptors. Planta Med. 2012; 78:1719-24.
• [32]Circosta C, De Pasquale R, Samperi S, Pino A, Occhiuto F. Biological and analytical characterization of two extracts from Valeriana officinalis. J Ethnopharmacol. 2007; 112:361-7.
• [33]Mussulini BHM, Leite CE, Zenki KC, Moro L, Baggio S, Rico EP, Rosemberg DB, Dias RD, Souza TM, Calcagnotto ME, Campos MM, Battastini AM, de Oliveira DL. Seizures induced by pentylenetetrazole in the adult zebrafish: a detailed behavioral characterization. PLoS One. 2013; 8: Article ID e54515
• [34]Afrikanova T, Serruys A-SK, Buenafe OEM, Clinckers R, Smolders I, de Witte P a M, Crawford AD, Esguerra CV. Validation of the zebrafish pentylenetetrazol seizure model: locomotor versus electrographic responses to antiepileptic drugs. PLoS One. 2013; 8:e54166.
• [35]Wong K, Stewart A, Gilder T, Wu N, Frank K, Gaikwad S, Suciu C, Dileo J, Utterback E, Chang K, Grossman L, Cachat J, Kalueff AV. Modeling seizure-related behavioral and endocrine phenotypes in adult zebrafish. Brain Res. 2010; 1348:209-15.
• [36]Baraban SC, Taylor MR, Castro PA, Baier H. Pentylenetetrazole induced changes in zebrafish behavior, neural activity and c-fos expression. Neuroscience. 2005; 131:759-68.
• [37]Baxendale S, Holdsworth CJ, Meza Santoscoy PL, Harrison MRM, Fox J, Parkin C a, Ingham PW, Cunliffe VT. Identification of compounds with anti-convulsant properties in a zebrafish model of epileptic seizures. Dis Model Mech. 2012; 5:773-84.
• [38]Berghmans S, Hunt J, Roach A, Goldsmith P. Zebrafish offer the potential for a primary screen to identify a wide variety of potential anticonvulsants. Epilepsy Res. 2007; 75:18-28.
• [39]Del Valle-Mojica LM, Cordero-Hernández JM, González-Medina G, Ramos-Vélez I, Berríos-Cartagena N, Torres-Hernández B, Ortíz JG. Aqueous and ethanolic Valeriana officinalis extracts change the binding of ligands to glutamate receptors. Evid Based Complement Alternat Med. 2011; 2011:Article ID 891819.
• [40]Gerlai R, Lee V, Blaser R. Effects of acute and chronic ethanol exposure on the behavior of adult zebrafish (Danio rerio). Pharmacol Biochem Behav. 2006; 85:752-61.
• [41]Hortopan GA, Dinday MT, Baraban SC. Zebrafish as a model for studying genetic aspects of epilepsy. Dis Model Mech. 2010; 3:144-8.
• [42]Norton W, Bally-Cuif L. Adult zebrafish as a model organism for behavioural genetics. BMC Neurosci. 2010; 11:90. BioMed Central Full Text
• [43]Fleming A. Zebrafish as an alternative model organism for disease modelling and drug discovery: implications for the 3Rs. Natl Cent Replace Refinement Reduct Anim Res 2007:1–7.
• [44]Nicholas JM, Ridsdale L, Richardson MP, Ashworth M, Gulliford MC. Trends in antiepileptic drug utilisation in UK primary care 1993–2008: cohort study using the General Practice Research Database. Seizure. 2012; 21:466-70.
• [45]Haroon A, Tripathi M, Khanam R, Vohora D. Antiepileptic drugs prescription utilization behavior and direct costs of treatment in a national hospital of India. Ann Indian Acad Neurol. 2012; 15:289-93.
• [46]Golmohammadi R, Pejhan A, Azhdari-Zarmehri H, Mohammad-Zadeh M. The role of ethanol on the anticonvulsant effect of valproic acid and cortical microvascular changes after epileptogenesis in mice. Neurol Sci. 2013; 34:1125-31.
• [47]Cuttle L, Munns AJ, Hogg NA, Scott JR, Hooper WD, Dickinson RG, Gillam EM. Phenytoin metabolism by human cytochrome P450: involvement of P450 3A and 2C forms in secondary metabolism and drug-protein adduct formation. Drug Metab Dispos. 2000; 28:945-50.
• [48]Miners JO, Birkett DJ. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol. 1998; 45:525-38.
• [49]Schmider J, Greenblatt DJ, von Moltke LL, Karsov D, Shader RI. Inhibition of CYP2C9 by selective serotonin reuptake inhibitors in vitro: studies of phenytoin p-hydroxylation. Br J Clin Pharmacol. 1997; 44:495-8.
• [50]Andersson T, Miners JO, Veronese ME, Birkett DJ. Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP3A isoforms. Br J Clin Pharmacol. 1994; 38:131-7.
• [51]Donovan JL, DeVane CL, Chavin KD, Wang J-S, Gibson BB, Gefroh HA, Markowitz JS. Multiple night-time doses of valerian (Valeriana officinalis) had minimal effects on CYP3A4 activity and no effect on CYP2D6 activity in healthy volunteers. Drug Metab Dispos. 2004; 32:1333-6.
• [52]Hellum BH, Hu Z, Nilsen OG. The induction of CYP1A2, CYP2D6 and CYP3A4 by six trade herbal products in cultured primary human hepatocytes. Basic Clin Pharmacol Toxicol. 2007; 100:23-30.
• [53]Hellum BH, Hu Z, Nilsen OG. Trade herbal products and induction of CYP2C19 and CYP2E1 in cultured human hepatocytes. Basic Clin Pharmacol Toxicol. 2009; 105:58-63.
• [54]Awad R, Levac D, Cybulska P, Merali Z, Trudeau VL, Arnason JT. Effects of traditionally used anxiolytic botanicals on enzymes of the gamma-aminobutyric acid (GABA) system. Can J Physiol Pharmacol. 2007; 85:933-42.
• [55]Oliva I, González-Trujano ME, Arrieta J, Enciso-Rodríguez R, Navarrete A. Neuropharmacological profile of hydroalcohol extract of Valeriana edulis ssp. procera roots in mice. Phytother Res. 2004; 18:290-6.
• [56]Celis CT, Rincón J, Guerrero MF. Pharmacological activity on central nervous system of the ethanolic extract and the alcaloidal fraction of Valeriana pavonii. Rev Col Cienc Quím Farm. 2007; 36:11-22.
• [57]Giraldo SE, Rincón J, Puebla P, Marder M, Wasowski C, Vergel N, Guerrero MF. Isovaleramide, an anticonvulsant molecule isolated from Valeriana pavonii. Biomedica. 2010; 30:245-50.
• [58]Alfaro JM, Ripoll-Gómez J, Burgos JS. Kainate administered to adult zebrafish causes seizures similar to those in rodent models. Eur J Neurosci. 2011; 33:1252-5.
• [59]Wong K, Elegante M, Bartels B, Elkhayat S, Tien D, Roy S, Goodspeed J, Suciu C, Tan J, Grimes C, Chung A, Rosenberg M, Gaikwad S, Denmark A, Jackson A, Kadri F, Chung KM, Stewart A, Gilder T, Beeson E, Zapolsky I, Wu N, Cachat J, Kalueff AV. Analyzing habituation responses to novelty in zebrafish (Danio rerio). Behav Brain Res. 2010; 208:450-7.
• [60]Siebel AM, Piato AL, Capiotti KM, Seibt KJ, Bogo MR, Bonan CD. PTZ-induced seizures inhibit adenosine deamination in adult zebrafish brain membranes. Brain Res Bull. 2011; 86:385-9.
• [61]Lee Y, Kim D, Kim Y-H, Lee H, Lee C-J. Improvement of pentylenetetrazol-induced learning deficits by valproic acid in the adult zebrafish. Eur J Pharmacol. 2010; 643:225-31.
• [62]Mares P. Age- and dose-specific anticonvulsant action of bumetanide in immature rats. Physiol Res. 2009; 58:927-30.
• [63]Ginsberg G, Hattis D, Sonawane B, Russ A, Banati P, Kozlak M, Smolenski S, Goble R. Evaluation of child/adult pharmacokinetic differences from a database derived from the therapeutic drug literature. Toxicol Sci. 2002; 66:185-200.